TC BIOPHARM (HOLDINGS) PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.479 USD | +4.15% |
|
-8.14% | -53.34% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Companyâs pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
| 1st Jan change | Capi. | |
|---|---|---|
| -53.34% | 4.73M | |
| -1.42% | 41.52B | |
| +42.15% | 39.9B | |
| +1.97% | 38.83B | |
| -14.19% | 26.05B | |
| +1.82% | 23.78B | |
| -24.55% | 18.26B | |
| -4.07% | 11.65B | |
| +21.36% | 11.53B | |
| +8.20% | 11.2B |
- Stock Market
- Equities
- TCBP Stock
- News TC Biopharm (Holdings) Plc
- TC Biopharm Completes $4 Million Stock Sale
